Coming Soon: Selected Patent Evaluations from the April 2017 Drug Repurposing Issue of ASSAY

The kind people at Mary Ann Liebert, Inc. Publishers have accelerated publication of ASSAY and Drug Development Technologies’ summer special issue: we got sufficient good manuscripts to warrant that. And lo!, this allows us to publish discussions of selected drug repurposing patent applications in a very timely manner. Once again, incredible pharmacological creativity from around the world! Here is the teaser for the 22 PCT documents from Q4/16 and Q1/17 that we have selected. Watch out for the full text at the ASSAY website.

Q4/2016

  • Desmopressin syergizes with docetaxel in prostate cancer (WO/2016/164482, Sunnybrook Research Institute, Toronto, Ontario, Canada; published October 6, 2016)
  • Wrapping up histone modulation in heart failure – news from the “inostat” drug family (WO/2016/164482, The University of North Carolina at Chapel Hill, Chapel Hill, NC; published October 13, 2016)
  • Teratogenic agents as cancer stem cell killers (WO/2016/176675, Nant Holdings IP, Culver City, CA, USA; published November 3, 2016)
  • The ACE inhibitor perindopril treat male genetic obesity (WO/2016/178591, Gene Predit SA, Cantanhede, Portugal; published November 10, 2016).
  • Deptropine and pizotifen are lysosome migration inhibitors (WO/2016/179481, inventor-applicants; published November 10, 2016)
  • Carbonic anhydrase inhibitors for clotting disorders (WO/2016/181135, The University of Bristol, Bristol, UK; published November 17, 2016)
  • “Setron” anti-nausea drugs for sensorineural hearing loss (WO/2016/184900, Sensorion SA, Montpellier, France; published November 24, 2016)
  • An opioid, an NSAID, an antiretroviral drug, and zebrafish: repurposing for Parkinson’s disease (WO/2016/190766, Technophage, S.A. et al., Portugal)
  • Biperiden treats Malt1+ cancers (WO/2016/193339, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; published December
    8, 2016)
  • Terazosine as an anti-aging drug (WO/2016/202099, inventor-applicants; published: December 22, 2016)
  • Imatinib for dry eye: exploiting a side effect (WO/2016/208961, Knotus Co., Ltd., Guri-si, Gyeonggi-do, Korea; published
    December 29, 2016)
  • Lorcaserin might improve weakness after sepsis (WO/2016/210431, Wright State University, Dayton, Ohio, USA; published December 29, 2016)

Q1/2017

  • Zoledronic acid: From erosive bone cancers to fatty liver disease (WO/2017/000902, Nanjing University, Jiangsu, China; published January 5, 2017)
  • Dipyramidole inhibits mesangial cell proliferation in renal diseases (WO/2017/007120, Cho Dang Pharm. Co. Ltd., Seoul, Korea; published January 12, 2017)
  • Amitryptilin inhibits CNS connexin hemichannels (WO/2017/009472, Theranexus, Lyon, France; published January 19, 2017)
  • Fluoxetine and vortioxetine for congenital myopathies (WO/2017/013031, Institut Pasteur, Paris, France et al.; published January 26, 2017)
  • Exhuming failed Alzheimer drugs for hematological immune diseases (WO/2017/019496, (Inventor-applicant; published February 2, 2017)
  • NMDA receptor blockers reduce blood-brain barrier permeability (WO/2017/021951, B. G. Negev Technologies and Applications, Ltd., Beer Sheva, Israel; published February 9, 2017)
  • Glutathione/gamma-glutamyl pathway modulators for persistent Lyme disease (WO/2017/034984, The Johns Hopkins University, Baltimore, MD, USA; published March 2, 2017)
  • GW-501516 and LY-518674: discontinued for major metabolic disorders, re-lifed for rare diseases? (WO/2017/044551, Mitobridge, Inc., Cambridge, MA, USA; published March 16, 2017)
  • Niclosamide for cancer: an exercise in extracting novelty from prior art (WO/2017/048197, Agency for Science, Technology and Research, Singapore; IFOM, the FIRC Institute of Molecular Oncology Foundation, Milano, Italy; published March 23, 2017)
  • Gentamycin’s nonsense suppression potential rests in its B1 component (WO/2017/049386, The University of British Columbia, Vancouver, Canada; published March 30, 2017)

Leave a Reply

Your email address will not be published. Required fields are marked *